Clinical research is any type of medical research that involves people. It includes studies that test new drugs, surgical procedures, or medical devices, as well as studies that simply observe how a disease progresses, what causes it, or who it affects. If you’ve ever wondered how a medication goes from a lab concept to a prescription your doctor can write, clinical research is the bridge that makes that possible.
How Clinical Research Differs From Lab Research
Before any treatment is tested in people, it typically goes through years of laboratory and animal studies. Clinical research is what happens next: real people volunteer to participate so that scientists can learn whether something actually works in the human body, and whether it’s safe. This is the stage where biology meets real life, accounting for the enormous variability in how different people respond to treatment.
There are two broad categories. Observational studies watch what happens without changing anything. Researchers might follow a group of people over time to see who develops a disease and what those individuals have in common, or they might compare people who already have a condition to those who don’t. Interventional studies, commonly called clinical trials, actively give participants a treatment, procedure, or device and measure the results. Interventional studies carry more scientific weight because researchers can control variables, randomize participants, and directly compare a new treatment against a placebo or an existing option.
The Four Phases of Clinical Trials
When a new drug is being developed, it moves through four distinct phases before and after reaching the market. Each phase asks a different question and involves a different scale of testing.
- Phase 1 focuses on safety and dosing. A small group of 20 to 100 people, sometimes healthy volunteers, receives the treatment for the first time. Researchers are primarily watching for harmful effects and figuring out what dose the body can tolerate. This phase typically lasts several months.
- Phase 2 shifts toward effectiveness. Up to several hundred people who have the disease or condition receive the treatment, and researchers begin measuring whether it actually helps. Side effects are still closely tracked. This phase can last anywhere from a few months to two years.
- Phase 3 is the large-scale confirmation. Between 300 and 3,000 volunteers with the condition participate, often at multiple hospitals or clinics. The goal is to confirm that the treatment works, compare it to existing options, and gather enough safety data to support regulatory approval. Phase 3 trials run for one to four years.
- Phase 4 happens after a drug has already been approved and is on the market. These studies involve thousands of people and monitor for rare or long-term side effects that may not have surfaced in earlier phases.
Most experimental treatments never make it through all four phases. A drug that looks promising in a small Phase 1 study may turn out to be ineffective or too risky when tested in larger groups.
Who Can Participate
Every clinical study has a specific set of eligibility rules. Inclusion criteria define who the researchers are looking for: typically characteristics like age range, a confirmed diagnosis, or a certain stage of disease. A study on a lung condition, for example, might require participants to be at least 40 years old, have had the diagnosis for at least a year, and have specific breathing test results on file.
Exclusion criteria filter out people whose participation could skew results or put them at risk. Someone with a second major health condition, an inability to attend follow-up appointments, or a high likelihood of dropping out might be excluded. These rules aren’t arbitrary. They exist to protect participants and to make sure the data is clean enough to draw reliable conclusions from.
Diversity in clinical trials has become a growing priority. The FDA now requires sponsors of certain clinical studies to submit diversity action plans outlining how they will recruit participants from underrepresented populations. Historically, many trials enrolled mostly white men, which left gaps in understanding how treatments work across different demographics.
How Participants Are Protected
Clinical research involving people is governed by layers of oversight designed to prevent harm and ensure ethical treatment. Before a study can begin, it must be reviewed and approved by an Institutional Review Board (IRB), an independent committee that evaluates whether the potential benefits of the research justify the risks. The IRB checks that participants will be selected fairly, that the study design minimizes danger, and that every volunteer gives informed consent before enrolling.
Informed consent means you receive a clear explanation of what the study involves, what the risks are, what alternatives exist, and that you can withdraw at any time without penalty. It’s not a single signature on a form. It’s an ongoing process throughout the study.
For larger or higher-risk trials, an additional body called a Data and Safety Monitoring Board reviews results while the study is still running. This independent group examines interim safety data at scheduled intervals and can recommend pausing or stopping a trial early. That might happen if participants are experiencing unexpected harm, if the treatment is clearly working and it would be unethical to keep giving some people a placebo, or if outside scientific developments change the risk calculation. The board defines specific triggers for these reviews before the study begins, so decisions aren’t made reactively.
Who Pays for Clinical Research
Clinical research is expensive, and funding comes from several sources. The National Institutes of Health is the world’s largest public funder of biomedical research, investing nearly $48 billion annually. Pharmaceutical and medical device companies fund a large share of clinical trials, particularly the later-phase studies needed for regulatory approval. Academic medical centers, nonprofit organizations, and international health agencies also sponsor research, often focusing on diseases that may not attract private investment.
The funding source matters because it can influence what questions get studied and how results are reported. Publicly funded research tends to focus on broader health questions, while industry-funded trials are typically designed to support a product’s path to market. Regulatory agencies require that funding sources and potential conflicts of interest be disclosed.
How Clinical Research Is Changing
Traditionally, participating in a clinical trial meant regular trips to a hospital or research center for check-ins, blood draws, and assessments. That model is shifting. Decentralized clinical trials move some or all study activities to participants’ homes and local healthcare facilities. Researchers recruit through social media, ship study medications directly to participants, collect health data through wearable devices, and conduct check-ins via telemedicine.
Fully decentralized trials eliminate site visits entirely, while hybrid models blend remote and in-person elements. These approaches can make participation more accessible for people who live far from major research centers, have mobility limitations, or can’t take time off work for frequent appointments. European and U.S. regulators are actively developing frameworks to ensure that decentralized trials maintain the same scientific rigor and safety standards as traditional ones.
The practical effect for participants is significant. A person in a rural area who previously would have been excluded simply by geography can now contribute to research that shapes the treatments available to everyone.